No­vo re­sumes We­govy 1.7 mg sup­ply; GSK’s £200M man­u­fac­tur­ing ex­pan­sion in the UK; Smart­Labs’ $48M Se­ries C

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

No­vo Nordisk re­sumed ship­ments of We­govy 1.7 mg dose ear­li­er this month, which had been pre­vi­ous­ly out of stock in the US in mid-De­cem­ber, a spokesper­son told End­points. “De­mand con­tin­ues to out­pace our in­creas­ing pro­duc­tion of We­govy. As a re­sult, we an­tic­i­pate po­ten­tial for on­go­ing sup­ply dis­rup­tions, and some pa­tients may con­tin­ue hav­ing dif­fi­cul­ty fill­ing We­govy pre­scrip­tions,” the spokesper­son added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER